Novartis AG
NOVN.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$273.23B
Close$
$157.68
28.5% upside
Current Fair Value
28.5% upsideUndervalued by 28.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $273.23 Billion |
|---|---|
| Enterprise Value | $314.54 Billion |
| Dividend Yield | $3.70 (3.11%) |
| Earnings per Share | $7.56 |
| Beta | 0.49 |
| Outstanding Shares | 1,905,000,000 |
Return
| Return on Equity | 30.50% |
|---|---|
| Return on Assets | 10.38% |
| Return on Invested Capital | 19.07% |
Valuation & Multiples
| P/E Ratio | 21.76 |
|---|---|
| PEG | -103.51 |
| Price to Sales | 4.38 |
| Price to Book Ratio | 5.84 |
| Enterprise Value to Revenue | 5.75 |
| Enterprise Value to EBIT | 18.31 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 1.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 21, 2026
EPS Estimate
$1.77
Average shareholder expectationRevenue Estimate
$11.38 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$1.90
Average shareholder expectationRevenue Estimate
$12.19 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Novartis AG
75,267 employees
CEO: Vasant Narasimhan Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...